Sanofi and GSK launch phase 1/2 study of their protein-based COVID-19 vaccine candidate

Vaccine uses same recombinant protein-based technology as one of Sanofi’s seasonal flu vaccines, coupled with adjuvant made by GSK, that acts as a booster to vaccine. Study has begun in 440 healthy adults in US, with aim of reaching final testing stage by December.

Reuters Health